Abbott (ABT) reported $10.36 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 4%. EPS of $1.09 for the same period compares to $0.98 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $10.42 billion, representing a surprise of -0.56%. The company delivered an EPS surprise of +1.87%, with the consensus EPS estimate being $1.07.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales- Nutrition- International: $1.19 billion compared to the $1.19 billion average estimate based on five analysts. The reported number represents a change of +0.1% year over year.
• Net sales- Nutrition- U.S. $955 million versus $925.35 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
• Net sales- Diagnostics- U.S. $871 million versus the five-analyst average estimate of $927.13 million. The reported number represents a year-over-year change of -6.4%.
• Net sales- Diagnostics- International: $1.18 billion compared to the $1.28 billion average estimate based on five analysts. The reported number represents a change of -7.8% year over year.
• Net sales- Nutrition: $2.15 billion versus $2.12 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change.
• Net sales- Medical Devices- Diabetes Care: $1.83 billion compared to the $1.82 billion average estimate based on six analysts. The reported number represents a change of +16.4% year over year.
• Net sales- Diagnostics: $2.05 billion versus $2.19 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -7.2% change.
• Net sales- Established Pharmaceuticals: $1.26 billion compared to the $1.23 billion average estimate based on six analysts. The reported number represents a change of +2.8% year over year.
• Net sales- Medical Devices- Vascular- Total: $710 million compared to the $704.85 million average estimate based on five analysts. The reported number represents a change of +3.1% year over year.
• Net sales- Medical Devices- Neuromodulation- Total: $228 million compared to the $235.53 million average estimate based on five analysts. The reported number represents a change of +0.9% year over year.
• Net sales- Medical Devices- Structural Heart- Total: $577 million versus the five-analyst average estimate of $592.77 million. The reported number represents a year-over-year change of +12%.
• Net sales- Medical Devices- Heart Failure- Total: $339 million versus the five-analyst average estimate of $325.77 million. The reported number represents a year-over-year change of +11.2%.

View all Key Company Metrics for Abbott here>>>

Shares of Abbott have returned -0.1% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research